This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.
Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
down by a third as investors all-but wrote off the drug in breast cancer. ... lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC).
JNJ-61186372 (JNJ-6372) is in trials as a treatment for adults with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion mutations, a patient group with no FDA-approved ... other cancer types including a rare head and neck cancer known as sinonasal
Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... tumours. Most of those gains dissipated after the
the first phase 3 cancer immunotherapy study to show an improvement in overall survival in this setting. ... The Tecentriq/Avastin combination is already approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a
cancer, a few months after it was cleared by the FDA with a slightly broader label. ... The top-selling checkpoint inhibitor has been given the green light by the EMA for previously-untreated metastatic or unresectable recurrent head and neck squamous
More from news
Approximately 0 fully matching, plus 61 partially matching documents found.
It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...